BioSpace News Archive

Abbott’s i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient’s bedside and obtain lab-quality results in 15 minutes.

BioLineRx Ltd. announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company’s American Depositary Shares and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant.

GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, is pleased to announce the publication in the esteemed scientific journal, Proceedings of the National Academy of Sciences (PNAS) that was spearheaded by Dr. Niña Caculitan, Director of Clinical Development.

Rallybio Corporation today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers will be presented at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting.

Asha Therapeutics announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference at 8:00am ET on April 9, 2024.

ADC Therapeutics SA announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious disease, announced that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open.